Chantix Anti Smoking
chantix news
Pfizer’s Chantix helps COPD patients quit smoking
Nov 8th
Pfizer has presented data which claims that significantly more smokers with mild-to-moderate chronic obstructive pulmonary disease who are treated with Chantix/Champix quit the habit compared with those on placebo.
The study, presented at American College of Chest Physicians annual meeting in San Diego, involved 499 adults suffering from mild-to-moderate COPD, who had smoked an average of 10 cigarettes or more per day in the year before enrollment. The participants, who had smoked for an average of 41 years, had a high level of nicotine dependence.
The primary efficacy endpoint was to compare 12 weeks of treatment with Chantix (varenicline) 1mg twice-daily to More >
Can Chantix Make A Comeback?
Oct 20th
Pfizer will restart TV advertising for its Chantix anti-smoking drug on Sunday, nine months after voluntarily putting the campaign on hold as worries about a link between the medicine and suicidal thoughts and actions grew.
The spots run 90 seconds–30 seconds more than the ones Pfizer (nyse: PFE – news – people ) ran for just four months last year–and hew to the same narrative as the old one, using a race between a tortoise and a Belgian hare to dramatize the fact that quitting smoking that favors the slow and steady–and that Chantix can help.
Side effect information takes up 41 More >
